Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab (BI 655130) induction therapy in moderate-to-severe ulcerative colitis after biologic failure
jRCT2080223993Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Spesolimab IV induction with Placebo IV induction (2 arms). Started Aug 2018; status: recruiting.
02
Drugs
spesolimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080223993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223993.